GHRH Analog + GHSR Agonist Blend
For Synergistic Growth Hormone Research
β οΈ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
π Contents
The CJC-1295 without DAC + Ipamorelin blend is a synergistic combination of two peptides that work through different but complementary pathways to stimulate natural growth hormone release [2][3][9]. This blend pairs a GHRH analog with a GHSR agonist to amplify both the frequency and duration of natural GH output [2][9].
CJC-1295 without DAC is a modified GRF (1-29) analog that extends each GH pulse, while Ipamorelin is a selective growth hormone secretagogue that triggers a clean GH pulse without raising cortisol or prolactin [2][4][9]. Together, they are often considered the most commonly recommended peptide stack for research on lean muscle growth and recovery [9]. This blend is available in pen and freeze-dried vial formulations for research purposes.
This blend works through two distinct but complementary mechanisms to stimulate growth hormone release:
Binds to GHRH receptors on pituitary somatotroph cells, extending the duration of each natural GH pulse [2][4][9]
Mimics ghrelin and triggers GH release from the pituitary without significantly raising cortisol or prolactin [2][4][9]
CJC-1295 amplifies the GH-releasing signal, while Ipamorelin triggers the actual releaseβa synergy that can produce greater GH elevation than either peptide alone [2][9]. The CJC-1295 without DAC version has a short half-life of approximately 30 minutes, preserving the body's natural pulsatile pattern of GH release and reducing the risk of receptor desensitization [2][5].
Studying IGF-1 elevation and protein synthesis for lean muscle development [9]
Clinical Studies on CJC-1295 (Teichman et al., JCEM 2006)
Synergistic Effects of the Blend
Research Protocols
Select your blend size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:
ποΈ Step 1: Select Your Blend Size
This is a 1:1 blend (5mg CJC-1295 + 5mg Ipamorelin = 10mg total)
Blend Size
10mg Blend (5+5)
Selected Dose
100 mcg each
Doses per Vial
50 doses
Pen Clicks
6 clicks
Volume
0.06 mL
Protocol Level
Level 2 (Standard)
Recommended Schedule
1-2 times daily - 5 days on, 2 days off
β οΈ Do not change your dose unless advised by a qualified professional.
π Protocol Level Summary
Based on research protocols: 100-200 mcg each, 1-2 times daily, 5 days on / 2 days off [1][4][9][11].
| Protocol Level | Target Dose | Frequency | Pen Clicks | Volume (mL) | Who It\'s For |
|---|---|---|---|---|---|
| Level 1 (Starting) | 50 mcg each | 1x daily | 3 clicks | 0.03 mL | New users, first 2 weeks |
| Level 2 (Standard) | 100 mcg each | 1-2x daily | 6 clicks | 0.06 mL | After 2 weeks, maintenance |
| Level 3 (Advanced) | 150 mcg each | 1-2x daily | 9 clicks | 0.09 mL | If more response needed |
| Level 4 (Maximum) | 200 mcg each | 1-2x daily | 12 clicks | 0.12 mL | Experienced users only |
β οΈ Do not change your dose unless advised by a qualified professional.
π Vial Users (Insulin Syringe)
Add 3mL of bacteriostatic water to your freeze-dried vial and mix gently. After reconstitution, use the table below to draw your dose:
Vial Size
10mg blend vial (5mg CJC-1295 + 5mg Ipamorelin) with 3mL bac water
| Dose | Frequency | Units on Syringe | Volume (mL) | Protocol Level |
|---|
β οΈ Always use a new sterile needle and syringe for each injection.
The CJC-1295 + Ipamorelin blend has been studied in clinical and research settings. The "no DAC" version has a short half-life (~30 minutes), which may reduce the risk of receptor desensitization compared to the long-acting DAC version [2][5].
Do not use if you:
β οΈ Warning: Neither CJC-1295 nor Ipamorelin is FDA-approved for any indication. These are research compounds. If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: July 2026
β οΈ FOR RESEARCH PURPOSES ONLY